Market closedNon-fractional
Kura Oncology/KURA
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Kura Oncology
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
Ticker
KURA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
142
Website
kuraoncology.com
Kura Oncology Metrics
BasicAdvanced
$1.6B
Market cap
-
P/E ratio
-$2.18
EPS
0.87
Beta
-
Dividend rate
Price and volume
Market cap
$1.6B
Beta
0.87
Financial strength
Current ratio
16.669
Quick ratio
16.47
Long term debt to equity
3.09
Total debt to equity
3.36
Interest coverage (TTM)
-94.35%
Management effectiveness
Return on assets (TTM)
-23.43%
Return on equity (TTM)
-37.34%
Valuation
Price to book
3.11
Price to tangible book (TTM)
3.11
Price to free cash flow (TTM)
-11.5
Growth
Earnings per share change (TTM)
6.84%
3-year earnings per share growth
7.91%
What the Analysts think about Kura Oncology
Analyst Ratings
Majority rating from 14 analysts.
Kura Oncology Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$50M
15.93%
Profit margin
0.00%
NaN%
Kura Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.53
-$0.50
-$0.55
-$0.59
-
Expected
-$0.55
-$0.55
-$0.55
-$0.55
-$0.63
Surprise
-3.62%
-9.00%
0.13%
7.34%
-
Kura Oncology News
AllArticlesVideos
Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
GlobeNewsWire·2 weeks ago
Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community
Business Wire·3 weeks ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kura Oncology stock?
Kura Oncology (KURA) has a market cap of $1.6B as of July 05, 2024.
What is the P/E ratio for Kura Oncology stock?
The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of July 05, 2024.
Does Kura Oncology stock pay dividends?
No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Kura Oncology dividend payment date?
Kura Oncology (KURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kura Oncology?
Kura Oncology (KURA) has a beta rating of 0.87. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Kura Oncology stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.